… the anti-breast cancer activity of raloxifene; clinical trials … its efficacy for breast cancer
prevention/risk reduction; and the … women who agreed to continue taking study drug, whether …

… of breast cancer risk reduction medications by breast cancer … for breast cancer risk
reduction in postmenopausal women … continued to be followed for death and cancer incidence …

… raloxifene in postmenopausal women with osteoporosis. … on the use of raloxifene for breast
cancer risk reduction in Korean … of raloxifene in women with osteoporosis and reduction of the …

… MORE (4-year treatment) and CORE (4-year additional treatment)… Predicting risk of breast
cancer in postmenopausal women by … of raloxifene on risk of breast cancer in postmenopausal …

… treat breast cancer in pre- or postmenopausal patients, and AIs are used only to treat
postmenopausal patients. … 4 years of treatment with raloxifene as Continued Outcomes Relevant to …

… clinical trials among postmenopausal women (24, 25) and may also be used off-label for
breast cancer risk reduction, these drugs have not yet been FDA-approved for this purpose, and …

… Raloxifene was also approved for postmenopausal women in … for breast cancer risk reduction
in women with a 5-year risk >3 … 4-year incidences of breast cancer and ER-positive breast …

… this 4-year trial period, a 72% reduction in invasive breast … in women in MORE who agreed
to continue in CORE. … , and in postmenopausal women raloxifene and exemestane should …

… high risk women on tamoxifen, with the greatest risk reduction … The chemopreventive effect
sustained beyond ten years of … raloxifene in postmenopausal women with increased BC risk (…

… risk of estrogen receptor-negative breast cancer (ER - BC) remains unknown. In addition,
raloxifene usage reduces the risk of … the incidence of estrogen receptor-positive breast cancer (…